Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › ivarmacitinib

ivarmacitinib

2 published articles · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Ivarmacitinib shows significant clinical improvement in a patient with alopecia areata and systemic lupus erythematosus
Rheumatology Sys. Review
Ivarmacitinib shows significant clinical improvement in a patient with alopecia areata and systemic lupus erythematosus Ivarmacitinib Shows Promise for Alopecia Areata and Lupus Hair Loss
This case report and literature review describes a 35-year-old woman with severe patchy alopecia and systemic lupus erythematosus who showed…
A new treatment may help patients with overlapping hair loss conditions like alopecia areata and systemic lupus erythematosus.
Frontiers Sep 14, 2026
Upadacitinib 30 mg tops JAK inhibitors for moderate-to-severe atopic dermatitis in network meta-analysis
Dermatology Sys. Review
Upadacitinib 30 mg tops JAK inhibitors for moderate-to-severe atopic dermatitis in network meta-analysis Upadacitinib Shows Highest Efficacy for Moderate to Severe Atopic Dermatitis
A systematic review and network meta-analysis of 9 RCTs (4261 adults) found upadacitinib 30 mg had the highest efficacy for EASI-75, IGA-AD …
A review of data from over 4,000 patients suggests upadacitinib may be the most effective oral treatment among several JAK inhibitors for se…
Jul 1, 2026